Under the new law, qualifying patients will be allowed to use and possess medical cannabis products containing no more than 0.9 percent THC. The law does not provide for in-state production of these products.
The measure expands the list of qualifying medical conditions, which previously only included those with intractable epilepsy, to include those with Alzheimer’s disease; ALS; Cancer, when such disease is diagnosed as end stage or the treatment produces related wasting illness, recalcitrant nausea and vomiting, or pain; Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis; Epilepsy or seizures; Multiple sclerosis; Parkinson’s disease; Human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS); and Sickle cell disease.
The new law also establishes a nine member commission to study “federal and state laws regarding medical cannabis” and advise lawmakers on “legislation to establish an effective, patient-focused medical cannabis program in this state upon the rescheduling or descheduling of marijuana from Schedule I of the federal Controlled Substances.” The commission must issue a report to lawmakers by January 2022.
The legislation makes it clear that a medical marijuana program may not operate in Tennessee until marijuana is “removed from Schedule I of the federal Controlled Substances Act.”
The new law takes effect immediately.